

Date: May 13, 2025

Ref. No.: KDL/SE/016/2025-26

| | |
|--|---|
| To, BSE Limited Corporate Relationship Department 25th Floor, Phiroze Jeejeebhoy Towers Dalal Street, Mumbai- 400001 Scrip Code: 543328 | To, National Stock Exchange of India Limited Exchange Plaza, Plot No. C-1, Block G, Bandra Kurla Complex, Bandra (East) Mumbai – 400051 NSE Symbol: KRSNAA |
|--|---|

Dear Sir/Madam,

Sub: Newspaper advertisement pertaining to the audited (Standalone and Consolidated) Financial Results for the quarter and year ended March 31, 2025.

Pursuant to Regulation 47 read with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copies of the newspaper advertisement pertaining to the audited (Standalone and Consolidated) Financial Results for the quarter and year ended March 31, 2025. The advertisements are published on May 13, 2025 in the following Newspapers:

1. Financial Express, English newspaper
2. Loksatta, Marathi newspaper

This will also be hosted on the Company's website at www.krsnaadiagnostics.com/investors

Request you to take the same on your records.

Thanking you,
Yours sincerely,

For Krsnaa Diagnostics Limited



Sujoy Sudipta Bose
Company Secretary & Compliance Officer
Encl: as above



KRSNAA DIAGNOSTICS LIMITED

Corporate Identity Number: L74900PN2010PLC138068

Registered and Corporate Office: S.No. 243/A, Hissa No. 6, CTS No. 4519, 4519/1, Near Chinchwad Station, Chinchwad, Taluka-Haveli, Pune - 411 019, Maharashtra.

Contact Person: Sujoy Sudipta Bose, Company Secretary and Compliance Officer

Telephone: +91 20 2740 2400; **E-mail:** investors@krsnaa.in; **Website:** www.krsnaadiagnostics.com

Company delivers Industry- Leading 37% Surge in Profit after tax, driven by robust 16% Revenue growth

Extract of Audited Consolidated Financial Results for the Quarter and Year Ended March 31, 2025

(₹ in Million, except per share data)

| Sl. No. | Particulars | Quarter Ended | | | Year Ended | |
|---------|---|----------------------------------|-----------------------------------|----------------------------------|-----------------------------|-----------------------------|
| | | March 31, 2025 (Refer Note 6) | December 31, 2024 (Un-audited) | March 31, 2024 (Refer Note 6) | March 31, 2025 (Audited) | March 31, 2024 (Audited) |
| 1. | Total Income | 1904.64 | 1837.49 | 1706.21 | 7426.95 | 6364.29 |
| 2. | Net Profit for the period (before Tax, Exceptional and/or Extraordinary items) | 286.05 | 254.78 | 226.05 | 1026.87 | 700.07 |
| 3. | Net Profit for the period before tax (after Exceptional and/or Extraordinary items) | 286.05 | 254.78 | 226.05 | 1026.87 | 700.07 |
| 4. | Net Profit for the period after tax (after Exceptional and/or Extraordinary items) | 206.78 | 194.15 | 187.27 | 776.08 | 568.37 |
| 5. | Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)] | 213.75 | 193.13 | 180.19 | 780.99 | 567.04 |
| 6. | Equity Share Capital | 161.45 | 161.45 | 161.45 | 161.45 | 161.45 |
| 7. | Earnings Per Share (Face Value of ₹ 5/- each) (for continuing and discontinued operations) - (Not annualised for quarters) | | | | | |
| | 1. Basic: | 6.40 | 6.01 | 5.80 | 24.04 | 17.90 |
| | 2. Diluted: | 6.28 | 5.88 | 5.70 | 23.56 | 17.31 |

Notes:

- These audited consolidated financial results ('consolidated financial results') of Krsnaa Diagnostics Limited ('the Holding Company') have been reviewed by the Audit Committee on May 12, 2025 and approved by the Board of Directors at its meeting held on May 12, 2025.
- The above consolidated financial results has been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) 2015, as amended.
- Standalone information :

| Sl. No. | Particulars | Quarter Ended | | | Year Ended | |
|---------|-------------------------------------|----------------------------------|-----------------------------------|----------------------------------|-----------------------------|-----------------------------|
| | | March 31, 2025 (Refer Note 6) | December 31, 2024 (Un-audited) | March 31, 2024 (Refer Note 6) | March 31, 2025 (Audited) | March 31, 2024 (Audited) |
| a | Revenue from Operations | 1746.53 | 1651.57 | 1593.91 | 6816.95 | 5900.19 |
| b | Profit Before Tax | 292.13 | 283.66 | 221.80 | 1096.02 | 719.45 |
| c | Net Profit After Tax for the period | 210.65 | 216.00 | 184.17 | 828.08 | 585.62 |
| d | Other Comprehensive Income/(Losses) | 5.76 | (1.00) | (7.78) | 3.76 | (1.83) |
| e | Total Comprehensive Income | 216.41 | 215.00 | 176.38 | 831.84 | 583.78 |

- The consolidated financial results for the year ended March 31, 2025 have been audited by the statutory auditors of the Holding Company as required under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) 2015, as amended. The statutory auditors of the Holding Company have expressed an unmodified opinion on these financial results.
- The Company's operations predominantly relate to providing diagnostic services in radiology and pathology services. The Chief Operating Decision Maker (CODM) reviews the operations of the Company as one operating segment. Hence, no separate segment information has been furnished herewith.
- The figures for quarter ended March 31, 2025 and March 31, 2024 are the balancing figures between audited figures in respect of full financial year and published year to date unaudited figures up to the end of the third quarter, which were subject to limited review by the statutory auditors.
- Pursuant to search and seizure proceedings initiated under the provisions of section 132(1) and section 133A of the Income Tax Act, 1961 ("the search operations"), the Holding Company had received assessment order dated March 31, 2024 for Assessment Year ("AY") for AY 22-23, and Orders for AY 23-24, AY 21-22, AY 20-21 and AY 17-18 were received during the last week of March 31, 2025 under the Income Tax Act, 1961 ("the Orders").
In the aforesaid Orders, the Income Tax authorities have made additions on account of undisclosed income and disallowance of certain deductions claimed by the Holding Company against the income tax returns filed for the relevant AY. Consequentially, it has resulted in a demand order of Rs. 513.86 million. Subsequently, the Holding Company has filed an appeal against the aforesaid assessment Orders with the Joint Commissioner (Appeals)/Commissioner of Income-Tax (Appeals). The Holding Company has paid amount under protest of INR.39.27 million against the Order of AY 22-23 and while making an appeal application against the Orders for the remaining AY's has requested to the Assistant Commissioner of Income Tax to adjust the tax refunds for AY 2024-25 to the extent of Rs. 63.50 million against the amounts to be paid under protest. These appeal applications have been acknowledged by the Commissioner of Income-Tax (Appeals).
The Holding Company has provided the requisite disclosure to the stock exchange with respect to the search operations and receipt of the Orders in accordance with Regulation 30 of the SEBI (LODR) Regulations, 2015 (as amended).
The management of the Holding Company, based on available information and underlying evidence and opinion obtained from its tax consultants and experts, it of view that the aforesaid demand orders are not tenable and will not have any material impact on the Group's financial position as of March 31, 2025, and on its performance for the year ended on that date.
- The board of directors have recommended the final dividend of Rs. 2.75 per equity share of the face value of Rs. 5 per equity share for the year ended March 31, 2025. The payment of dividend is subject to approval of shareholders at the ensuing Annual General meeting of the company.
- Previous quarter/year figures have been regrouped/ rearranged wherever considered necessary.



On behalf of the Board of Directors
For Krsnaa Diagnostics Limited

Sd/-
Rajendra Mutha
Chairman & Whole-time Director
DIN: 01066737

Place: Pune
Date: May 12, 2025



KRSNAA DIAGNOSTICS LIMITED

Corporate Identity Number: L74900PN2010PLC138068

Registered and Corporate Office: S.No. 243/A, Hissa No. 6, CTS No. 4519, 4519/1, Near Chinchwad Station, Chinchwad, Taluka-Haveli, Pune - 411 019, Maharashtra.

Contact Person: Sujoy Sudipta Bose, Company Secretary and Compliance Officer

Telephone: +91 20 2740 2400; E-mail: investors@krsnaa.in; Website: www.krsnaadiagnostics.com

Company delivers Industry- Leading 37% Surge in Profit after tax, driven by robust 16% Revenue growth

Extract of Audited Consolidated Financial Results for the Quarter and Year Ended March 31, 2025

(₹ in Million, except per share data)

| Sl. No. | Particulars | Quarter Ended | | | Year Ended | |
|---------|---|----------------------------------|-----------------------------------|----------------------------------|-----------------------------|-----------------------------|
| | | March 31, 2025 (Refer Note 6) | December 31, 2024 (Un-audited) | March 31, 2024 (Refer Note 6) | March 31, 2025 (Audited) | March 31, 2024 (Audited) |
| 1. | Total Income | 1904.64 | 1837.49 | 1706.21 | 7426.95 | 6364.29 |
| 2. | Net Profit for the period (before Tax, Exceptional and/or Extraordinary items) | 286.05 | 254.78 | 226.05 | 1026.87 | 700.07 |
| 3. | Net Profit for the period before tax (after Exceptional and/or Extraordinary items) | 286.05 | 254.78 | 226.05 | 1026.87 | 700.07 |
| 4. | Net Profit for the period after tax (after Exceptional and/or Extraordinary items) | 206.78 | 194.15 | 187.27 | 776.08 | 568.37 |
| 5. | Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)] | 213.75 | 193.13 | 180.19 | 780.99 | 567.04 |
| 6. | Equity Share Capital | 161.45 | 161.45 | 161.45 | 161.45 | 161.45 |
| 7. | Earnings Per Share (Face Value of ₹ 5/- each) (for continuing and discontinued operations) - (Not annualised for quarters) | | | | | |
| | 1. Basic: | 6.40 | 6.01 | 5.80 | 24.04 | 17.90 |
| | 2. Diluted: | 6.28 | 5.88 | 5.70 | 23.56 | 17.31 |

Notes:

- These audited consolidated financial results ('consolidated financial results') of Krsnaa Diagnostics Limited ('the Holding Company') have been reviewed by the Audit Committee on May 12, 2025 and approved by the Board of Directors at its meeting held on May 12, 2025.
- The above consolidated financial results has been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) 2015, as amended.
- Standalone information :

| Sl. No. | Particulars | Quarter Ended | | | Year Ended | |
|---------|-------------------------------------|----------------------------------|-----------------------------------|----------------------------------|-----------------------------|-----------------------------|
| | | March 31, 2025 (Refer Note 6) | December 31, 2024 (Un-audited) | March 31, 2024 (Refer Note 6) | March 31, 2025 (Audited) | March 31, 2024 (Audited) |
| a | Revenue from Operations | 1746.53 | 1651.57 | 1593.91 | 6816.95 | 5900.19 |
| b | Profit Before Tax | 292.13 | 283.66 | 221.80 | 1096.02 | 719.45 |
| c | Net Profit After Tax for the period | 210.65 | 216.00 | 184.17 | 828.08 | 585.62 |
| d | Other Comprehensive Income/(Losses) | 5.76 | (1.00) | (7.78) | 3.76 | (1.83) |
| e | Total Comprehensive Income | 216.41 | 215.00 | 176.38 | 831.84 | 583.78 |

- The consolidated financial results for the year ended March 31, 2025 have been audited by the statutory auditors of the Holding Company as required under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) 2015, as amended. The statutory auditors of the Holding Company have expressed an unmodified opinion on these financial results.
- The Company's operations predominantly relate to providing diagnostic services in radiology and pathology services. The Chief Operating Decision Maker (CODM) reviews the operations of the Company as one operating segment. Hence, no separate segment information has been furnished herewith.
- The figures for quarter ended March 31, 2025 and March 31, 2024 are the balancing figures between audited figures in respect of full financial year and published year to date unaudited figures up to the end of the third quarter, which were subject to limited review by the statutory auditors.
- Pursuant to search and seizure proceedings initiated under the provisions of section 132(1) and section 133A of the Income Tax Act, 1961 ("the search operations"), the Holding Company had received assessment order dated March 31, 2024 for Assessment Year ("AY") for AY 22-23, and Orders for AY 23-24, AY 21-22, AY 20-21 and AY 17-18 were received during the last week of March 31, 2025 under the Income Tax Act, 1961 ("the Orders").
In the aforesaid Orders, the Income Tax authorities have made additions on account of undisclosed income and disallowance of certain deductions claimed by the Holding Company against the income tax returns filed for the relevant AY. Consequentially, it has resulted in a demand order of Rs. 513.86 million. Subsequently, the Holding Company has filed an appeal against the aforesaid assessment Orders with the Joint Commissioner (Appeals)/Commissioner of Income-Tax (Appeals). The Holding Company has paid amount under protest of INR.39.27 million against the Order of AY 22-23 and while making an appeal application against the Orders for the remaining AY's has requested to the Assistant Commissioner of Income Tax to adjust the tax refunds for AY 2024-25 to the extent of Rs. 63.50 million against the amounts to be paid under protest. These appeal applications have been acknowledged by the Commissioner of Income-Tax (Appeals).
The Holding Company has provided the requisite disclosure to the stock exchange with respect to the search operations and receipt of the Orders in accordance with Regulation 30 of the SEBI (LODR) Regulations, 2015 (as amended).
The management of the Holding Company, based on available information and underlying evidence and opinion obtained from its tax consultants and experts, it of view that the aforesaid demand orders are not tenable and will not have any material impact on the Group's financial position as of March 31, 2025, and on its performance for the year ended on that date.
- The board of directors have recommended the final dividend of Rs. 2.75 per equity share of the face value of Rs. 5 per equity share for the year ended March 31, 2025. The payment of dividend is subject to approval of shareholders at the ensuing Annual General meeting of the company.
- Previous quarter/year figures have been regrouped/ rearranged wherever considered necessary.



On behalf of the Board of Directors
For Krsnaa Diagnostics Limited

Sd/-
Rajendra Mutha
Chairman & Whole-time Director
DIN: 01066737

Place: Pune
Date: May 12, 2025